HIPK2 Antibody (493918) [Unconjugated]

HIPK2 was detected in immersion fixed MCF-7 human breast cancer cell line using Mouse Anti-Human HIPK2 Monoclonal Antibody (Catalog # MAB9307) at 8 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm and nuclei. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

• Reactivity: Hu
• Applications: ICC/IF
• Clone: 493918
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

HIPK2 Antibody (493918) [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human HIPK2
  Met765-Ser924
  Accession # Q9H2X6
• Specificity: Detects human HIPK2 in direct ELISAs.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry 5-25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for HIPK2 Antibody (493918) [Unconjugated]

• DKFZp686K02111
• EC 2.7.11.1
• FLJ23711
• hHIPk2
• HIPK2
• homeodomain interacting protein kinase 2
• homeodomain-interacting protein kinase 2
• PRO0593
• Stank

Background

Homeodomain-interacting protein kinase-2 (HIPK2) is a serine/threonine kinase which interacts with transcription factors, including p53, CREB1, SMAD1, SMAD2, RUNX1 and others, and can act as a corepressor or coactivator depending on the transcription factor and subcellular localization.  Post-translational modifications control HIPK2 activity, including phosphorylation, small ubiquitin-like modifier modification, acetylation, and ubiquitination. HIPK2 regulation of cell proliferation makes it a key effector of proliferative diseases including cancer and kidney fibrosis. For example, HIPK2 can repress the proliferative Wnt-1/b-catenin pathway and HIF-1, promote apoptosis by activation of p53 and repression of delta Np63 alpha , MDM2 and CtBP, and its activity is enhanced by anti-cancer drugs such as cisplatin and etoposide.  HIPK2 oncorepession can be blocked by cytoplasmic localization, hypoxia, gene mutation and loss of heterozygosity.

 

(Saul VV and Schmitz ML, J Mol Med (Berl). 2013 Sep;91(9):1051-8.)  (Saul VV and Schmitz ML, J Mol Med (Berl). 2013 Sep;91(9):1051-8.)  (D'Orazi G, et al, J Exp Clin Cancer Res. 2012 Aug 13;31:63. )

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q9H2X6()